Involvement of alpha-2 adrenoceptors in the effects of moxonidine on intestinal motility and fluid transport.
The aims of this study were to examine how the imidazoline (I)1/alpha-2 receptor agonist moxonidine and the putative endogenous imidazoline receptor agonist agmatine might affect intestinal motility and fluid transport. The effects of moxonidine were compared with those of UK 14,304, a highly selective alpha-2 adrenoceptor agonist with very low affinity for I1 receptors. Moxonidine and UK 14,304 inhibited the peristaltic reflex in the isolated rat ileum. The inhibitory effects were antagonized by the selective alpha-2 adrenoceptor antagonist yohimbine and the I1/alpha-2 antagonist efaroxan and almost completely blocked by the irreversible alpha-2 adrenoceptor antagonist EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline), which has a low affinity for imidazoline receptors. Yohimbine (3 microM) and efaroxan (0.01 and 1 microM) caused parallel rightward shifts to the concentration-response curves of moxonidine and UK 14,304, yielding pKB values corresponding to those at alpha-2 binding sites. Moxonidine induced dose-dependent proabsorptive effects in the jejunum and ileum and also reversed the secretory phase of the vasoactive intestinal peptide-induced responses. The degree of antagonism by yohimbine and efaroxan was similar against moxonidine and UK 14,304 on the proabsorptive and antisecretory effects. We conclude that the effects of moxonidine in mediating inhibition of intestinal motility and enhancing fluid transport are attributed predominantly to interaction with alpha-2 adrenoceptors. Agmatine had no effect on peristalsis but significantly decreased the rate of fluid absorption from the jejunum and ileum, an effect in contrast to moxonidine. A physiological role for agmatine in the regulation of intestinal transport remains to be clarified.
Liu
L
L
Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia.
Coupar
I M
IM
D058647:Adrenergic alpha-2 Receptor Agonists; D000376:Agmatine / Q000494:pharmacology; D000818:Animals; D001834:Body Water / Q000378:metabolism*; D000068438:Brimonidine Tartrate; D004305:Dose-Response Relationship, Drug; D005769:Gastrointestinal Motility / Q000187:drug effects*; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D010528:Peristalsis / Q000187:drug effects; D011804:Quinolines / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D058647:Adrenergic alpha-2 Receptor Agonists; D007093:Imidazoles; D011804:Quinolines; D011810:Quinoxalines; D018341:Receptors, Adrenergic, alpha-2; D015016:Yohimbine; D014660:Vasoactive Intestinal Peptide; D000068438:Brimonidine Tartrate; C000470:EEDQ; D000376:Agmatine; C043482:moxonidine